Physician profile
Charles L Smith
NPI 1649222928
$3,116.70
in general payments reported to CMS, 2019-2025
35 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $192 · 2021: $122 · 2022: $246 · 2023: $480 · 2024: $612 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $449.63 | 2019-2025 | |
| Novo Nordisk INC | $398.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $288.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $256.47 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $202.35 | 2019-2025 | Repatha, Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $142.91 | 2019-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.04 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $127.03 | 2019-2021 | |
| Abbott Laboratories | $112.59 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.46 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $79.11 | 2020-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $64.52 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.32 | 2022-2024 | |
| Exact Sciences Corporation | $63.63 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $53.58 | 2022-2025 | Nexletol |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $52.57 | 2023-2024 | Ubrelvy |
| Sunovion Pharmaceuticals INC. | $52.40 | 2019-2021 | |
| Vital Connect, INC | $51.21 | 2023 | Vitalpatch Rtm |
| Astellas Pharma US INC | $51.12 | 2019-2020 | |
| Dexcom, INC. | $48.63 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $47.91 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $35.40 | 2019 | |
| Shire North American Group INC | $33.50 | 2019 | |
| Boston Scientific Corporation | $33.42 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Amarin Pharma, INC. | $24.67 | 2019-2020 | |
| Mylan Specialty L.P. | $24.06 | 2019 | |
| Hikma Pharmaceuticals USA | $23.94 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $18.50 | 2019 | |
| Inspire Medical Systems, INC. | $16.88 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $16.51 | 2025 | Symbravo |
| Idorsia Pharmaceuticals US INC | $14.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.17 | 2024 | Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $12.13 | 2020 | |
| Merck Sharp & Dohme LLC | $12.08 | 2020 | |
| Allergan, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.